Noelle Cocoros

Noelle Cocoros


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2021 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
NCNoelle Cocoros
Noelle Cocoros
ESElisabeth Svensson
Elisabeth Svensson
SSSzimonetta Komjáthine Szépligeti
Szimonetta Komjáthine Szépligeti
SVSøren Viborg Vestergaard
Søren Viborg Vestergaard
PSPéter Szentkúti
Péter Szentkúti
VHVictor W. Henderson
Victor W. Henderson
Parkinson disease (PD)—characterized by cardinal features of bradykinesia, rest tremor, and rigidity1 — is the second most common neurodegenerative disease. Incidence and prevalence estimates vary depending on source, age, and case definitions.2-4 In Denmark, incidence has been estimated at 23 per 100 000 person-years,5 while a systematic literature review of European studies reported an incidence range from 5 to 346 per 100 000.6 In the US, a study that estimated incidence over 30 years reported a rate of 17 per 100 000 person-years for men and women combined.7 The pathological cascade preceding neurological symptoms is hypothesized to span 10 to 20 years or longer.8 While most PD cases are idiopathic, others are linked to known genetic variants3 or to suspected lifestyle factors and environmental exposures.2,3

16 December 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
SKSheryl A. Kluberg
Sheryl A. Kluberg
LHLaura Hou
Laura Hou
SDSarah K. Dutcher
Sarah K. Dutcher
MBMonisha Billings
Monisha Billings
BKBrian Kit
Brian Kit
NCNoelle Cocoros
Noelle Cocoros
Purpose: Health plan claims may provide complete longitudinal data for timely, real‐world population‐level COVID‐19 assessment. However, these data often lack laboratory results, the standard for COVID‐19 diagnosis.Methods: We assessed the validity of ICD‐10‐CM diagnosis codes for identifying patients hospitalized with COVID‐19 in U.S. claims databases, compared to linked laboratory results, among six Food and Drug Administration Sentinel System data partners (two large national insurers, four integrated delivery systems) from February 20–October 17, 2020. We identified patients hospitalized with COVID‐19 according to five ICD‐10‐CM diagnosis code‐based algorithms, which included combinations of codes U07.1, B97.29, general coronavirus codes, and diagnosis codes for severe symptoms. We calculated the positive predictive value (PPV) and sensitivity of each algorithm relative to laboratory test results. We stratified results by data source type and across three time periods: February 20–March 31 (Time A), April 1–30 (Time B), May 1–October 17 (Time C).Results: The five algorithms identified between 34 806 and 47 293 patients across the study periods; 23% with known laboratory results contributed to PPV calculations. PPVs were high and similar across algorithms. PPV of U07.1 alone was stable around 93% for integrated delivery systems, but declined over time from 93% to 70% among national insurers. Overall PPV of U07.1 across all data partners was 94.1% (95% CI, 92.3%–95.5%) in Time A and 81.2% (95% CI, 80.1%–82.2%) in Time C. Sensitivity was consistent across algorithms and over time, at 94.9% (95% CI, 94.2%–95.5%).Conclusion: Our results support the use of code U07.1 to identify hospitalized COVID‐19 patients in U.S. claims data.

1 January 2016 in Critical Care Medicine
Verified
Journal Article
Closed access
NCNoelle Cocoros
Noelle Cocoros
KKKen Kleinman
Ken Kleinman
GPGregory P. Priebe
Gregory P. Priebe
JGJames E. Gray
James E. Gray
LLLatania K. Logan
Latania K. Logan
GLGrace M. Lee
Grace M. Lee
Objectives: To identify a pediatric ventilator-associated condition definition for use in neonates and children by exploring whether potential ventilator-associated condition definitions identify patients with worse outcomes. Design: Retrospective cohort study and a matched cohort analysis. Setting: Pediatric, cardiac, and neonatal ICUs in five U.S. hospitals. Patients: Children 18 years old or younger ventilated for at least 1 day. Interventions: None. Measurements and Main Results: We evaluated the evidence of worsening oxygenation via a range of thresholds for increases in daily minimum fraction of inspired oxygen (by 0.20, 0.25, and 0.30) and daily minimum mean airway pressure (by 4, 5, 6, and 7 cm H2O). We required worsening oxygenation be sustained for at least 2 days after at least 2 days of stability. We matched patients with a ventilator-associated condition to those without and used Cox proportional hazard models with frailties to examine associations with hospital mortality, hospital and ICU length of stay, and duration of ventilation. The cohort included 8,862 children with 10,209 hospitalizations and 77,751 ventilator days. For the fraction of inspired oxygen 0.25/mean airway pressure 4 definition (i.e., increase in minimum daily fraction of inspired oxygen by 0.25 or mean airway pressure by 4), rates ranged from 2.9 to 3.2 per 1,000 ventilator days depending on ICU type; the fraction of inspired oxygen 0.30/mean airway pressure 7 definition yielded ventilator-associated condition rates of 1.1–1.3 per 1,000 ventilator days. All definitions were significantly associated with greater risk of hospital death, with hazard ratios ranging from 1.6 (95% CI, 0.7–3.4) to 6.8 (2.9–16.0), depending on thresholds and ICU type. Each definition was associated with prolonged hospitalization, time in ICU, and duration of ventilation, among survivors. The advisory board of the study proposed using the fraction of inspired oxygen 0.25/mean airway pressure 4 thresholds to identify pediatric ventilator-associated conditions in ICUs. Conclusions: Pediatric patients with ventilator-associated conditions are at substantially higher risk for mortality and morbidity across ICUs, regardless of thresholds used. Next steps include identification of risk factors, etiologies, and preventative measures for pediatric ventilator-associated conditions.

20 August 2013 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
NCNoelle Cocoros
Noelle Cocoros
TLTimothy L. Lash
Timothy L. Lash
ADAlfred DeMaria
Alfred DeMaria
MKMichael Klompas
Michael Klompas
Background: Obesity was recognized as in independent risk factor for influenza during the 2009 H1N1 influenza pandemic.Objectives: We evaluated the association between body mass index (BMI) and influenza‐like illness (ILI) during two non‐pandemic influenza seasons (2003–2004 and 2004–2005) and during the spring and fall waves of the 2009 H1N1 pandemic.Methods: Adults with severe (inpatient) and mild (outpatient) ILI were compared to those without ILI using a case‐cohort design. The study was nested among those insured by a single health insurance company, receiving care from a large multispecialty practice. Data were collected from insurance claims and the electronic health record. The primary exposure was obesity (BMI ≥ 30·0 kg/m2).Results: Across three seasons, the crude and adjusted ORs for obesity and severe ILI were 1·65 (95% CI 1·31, 2·08) and 1·23 (95% CI 0·97, 1·57), respectively. An association was observed for those aged 20–59 years (adjusted OR 1·92, 95% CI 1·26, 2·90), but not for those 60 and older (adjusted OR 1·08, 95% CI 0·80, 1·46). The adjusted ORs for obesity and severe ILI in 2003–2004, 2004–2005, and during H1N1 were 1·14 (95% CI 0·80, 1·64), 1·24 (95% CI 0·86, 1·79), and 1·76 (95% CI 0·91, 3·42), respectively. Among those with a Charlson Comorbidity Index score of zero, the adjusted ORs for 2003–2004, 2004–2005, and H1N1 were 1·60 (95% CI 0·93, 2·76), 1·43 (95% CI 0·80, 2·56), and 1·90 (95% CI 0·68, 5·27), respectively.Conclusions: Our results suggest a small to moderate association between obesity and hospitalized ILI among adults.

1 March 2023 in Journal of Public Health Management & Practice
Verified
Journal Article
Closed access
KHKatherine H. DrPH Hohman
Katherine H. DrPH Hohman
AMAmanda K. Mph Martinez
Amanda K. Mph Martinez
MKMichael Klompas
Michael Klompas
EKEmily M. Kraus
Emily M. Kraus
WLWenjun Li
Wenjun Li
HWHilary K. Wall
Hilary K. Wall
Context: Electronic health record (EHR) data can potentially make chronic disease surveillance more timely, actionable, and sustainable. Although use of EHR data can address numerous limitations of traditional surveillance methods, timely surveillance data with broad population coverage require scalable systems. This report describes implementation, challenges, and lessons learned from the Multi-State EHR-Based Network for Disease Surveillance (MENDS) to help inform how others work with EHR data to develop distributed networks for surveillance. Program: Funded by the Centers for Disease Control and Prevention (CDC), MENDS is a data modernization demonstration project that aims to develop a timely national chronic disease sentinel surveillance system using EHR data. It facilitates partnerships between data contributors (health information exchanges, other data aggregators) and data users (state and local health departments). MENDS uses query and visualization software to track local emerging trends. The program also uses statistical and geospatial methods to generate prevalence estimates of chronic disease risk measures at the national and local levels. Resulting data products are designed to inform public health practice and improve the health of the population. Implementation: MENDS includes 5 partner sites that leverage EHR data from 91 health system and clinic partners and represents approximately 10 million patients across the United States. Key areas of implementation include governance, partnerships, technical infrastructure and support, chronic disease algorithms and validation, weighting and modeling, and workforce education for public health data users. Discussion: MENDS presents a scalable distributed network model for implementing national chronic disease surveillance that leverages EHR data. Priorities as MENDS matures include producing prevalence estimates at various geographic and subpopulation levels, developing enhanced data sharing and interoperability capacity using international data standards, scaling the network to improve coverage nationally and among underrepresented geographic areas and subpopulations, and expanding surveillance of additional chronic disease measures and social determinants of health.

5 December 2016 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
NCNoelle Cocoros
Noelle Cocoros
GPGregory P. Priebe
Gregory P. Priebe
LLLatania K. Logan
Latania K. Logan
SCSusan Coffin
Susan Coffin
GLGitte Larsen
Gitte Larsen
GLGrace M. Lee
Grace M. Lee
OBJECTIVE: Adult ventilator-associated event (VAE) definitions include ventilator-associated conditions (VAC) and subcategories for infection-related ventilator-associated complications (IVAC) and possible ventilator-associated pneumonia (PVAP). We explored these definitions for children.DESIGN: Retrospective cohortSETTING: Pediatric, cardiac, or neonatal intensive care units (ICUs) in 6 US hospitalsPATIENTS: Patients ≤18 years old ventilated for ≥1 dayMETHODS: We identified patients with pediatric VAC based on previously proposed criteria. We applied adult temperature, white blood cell count, antibiotic, and culture criteria for IVAC and PVAP to these patients. We matched pediatric VAC patients with controls and evaluated associations with adverse outcomes using Cox proportional hazards models.RESULTS: In total, 233 pediatric VACs (12,167 ventilation episodes) were identified. In the cardiac ICU (CICU), 62.5% of VACs met adult IVAC criteria; in the pediatric ICU (PICU), 54.2% of VACs met adult IVAC criteria; and in the neonatal ICU (NICU), 20.2% of VACs met adult IVAC criteria. Most patients had abnormal white blood cell counts and temperatures; we therefore recommend simplifying surveillance by focusing on “pediatric VAC with antimicrobial use” (pediatric AVAC). Pediatric AVAC with a positive respiratory diagnostic test (“pediatric PVAP”) occurred in 8.9% of VACs in the CICU, 13.3% of VACs in the PICU, and 4.3% of VACs in the NICU. Hospital mortality was increased, and hospital and ICU length of stay and duration of ventilation were prolonged among all pediatric VAE subsets compared with controls.CONCLUSIONS: We propose pediatric AVAC for surveillance related to antimicrobial use, with pediatric PVAP as a subset of AVAC. Studies on generalizability and responsiveness of these metrics to quality improvement initiatives are needed, as are studies to determine whether lower pediatric VAE rates are associated with improvements in other outcomes.Infect Control Hosp Epidemiol 2017;38:327–333